Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether surgical thrombectomy changes major adverse events compared with mechanical thrombectomy (very low certainty).
1 finding from 1 review
Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether mechanical thrombectomy changes major adverse events compared with pulse spray technique (very low certainty).
1 finding from 1 review
Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether surgical thrombectomy changes major adverse events compared with continuous infusion (very low certainty).
1 finding from 1 review
Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether pharmacomechanical thrombolysis (Cragg® catheter) changes major adverse events compared with pulse spray technique (very low certainty).
1 finding from 1 review
Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether surgical thrombectomy changes major adverse events compared with pulse spray technique (very low certainty).
1 finding from 1 review
Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether surgical thrombectomy changes major adverse events compared with different types of endovascular interventions (very low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found